Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Go back to Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 0.55 +0.05 (10.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.50 | 52 Week High | $9.70 | |||
| Open | $0.48 | 52 Week Low | $2.78 | |||
| Day High | $0.56 | P/E | N/A | |||
| Day Low | $0.47 | EPS | $0.00 | |||
| Volume | 209,953 | |||||
